Given that prophylactic LDA may be associated with an increased risk of intracranial haemorrhage in healthy subjects [73], the question of whether all SLE patients with a low-risk aPL profile and no history of clinical thrombosis should receive a LDA is controversial. This evidence concerns the gene FASLG and Venous thrombosis.